Advertisement

Methenamine as prophylaxis for recurrent urinary tract infections: an overview of the ALTAR trial

Published:October 18, 2022DOI:https://doi.org/10.1016/j.ogrm.2022.09.004

      Abstract

      Current recommended treatment for recurrent uncomplicated urinary tract infections in women includes low-dose daily antibiotics. The UK Antimicrobial Resistance Strategy document underlines the importance of non-antibiotic preventive treatments for common infections such as UTIs. The ALTAR trial investigated the clinical effectiveness of one such non-antibiotic treatment, the urinary antiseptic Methenamine Hippurate in the context of a randomised, open-label, pragmatic, two-arm non-inferiority trial with the comparator of daily low-dose antibiotics. Non-inferiority was confirmed in this study and the authors recommend that it should now be considered as a first-line preventive treatment for recurrent uncomplicated urinary tract infections in women.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Obstetrics, Gynaecology and Reproductive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      Further reading

      1. European Association of Urology. EAU Guidelines - Urological Infections. Edn. presented at the EAU Annual Congress Amsterdam the Netherlands 2020. ISBN 978-94-92671-07-3.

        • Forbes R.
        • Ali A.
        • Abouhajar A.
        • et al.
        ALternatives to prophylactic Antibiotics for the treatment of Recurrent urinary tract infection in women (ALTAR): study protocol for a multicentre, pragmatic, patient-randomised, non-inferiority trial.
        Trials. 2018; 19 (Published 2018 Nov 9): 616https://doi.org/10.1186/s13063-018-2998-4
        • Lee B.S.
        • Bhuta T.
        • Simpson J.M.
        • Craig J.C.
        Methenamine hippurate for preventing urinary tract infections.
        Cochrane Database Syst Rev. 2012; 10 (Published 2012 Oct 17): CD003265https://doi.org/10.1002/14651858.CD003265.pub3
        • National Institute for Health and Care Excellence, Guideline NG112, Urinary tract infection (recurrent): antimicrobial prescribing 2018
        • UK Government, Tackling antimicrobial resistance 2019–2024: The UK’s five-year national action plan